Clinical pharmacological study of a plasma‐derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors – Phase I trial
暂无分享,去创建一个
Y. Ohashi | J. Takamatsu | A. Shirahata | T. Matsushita | M. Shima | K. Fukutake | S. Higasa | J. Mimaya | N. Takata | H. Saito | H. Hanabusa | M. Sakai | K. Kawakami | Y. Takashima | H. Takedani | A. Tawa
[1] Y. Nakatomi,et al. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent. , 2010, Thrombosis research.
[2] J. Rosing,et al. Factor IX mutants with enhanced catalytic activity , 2009, Journal of thrombosis and haemostasis : JTH.
[3] B. Scharling,et al. Evaluation of the safety and pharmacokinetics of a fast‐acting recombinant FVIIa analogue, NN1731, in healthy male subjects , 2009, Journal of thrombosis and haemostasis : JTH.
[4] R. Bayer,et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives , 2008, Thrombosis and Haemostasis.
[5] U. Martinowitz,et al. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] M. Economou,et al. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[7] S. Knaub,et al. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers , 2007, Thrombosis and Haemostasis.
[8] G. Young,et al. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] U. Hedner. Dosing with recombinant factor viia based on current evidence. , 2004, Seminars in hematology.
[10] Y. Nakatomi,et al. A novel therapeutic approach combining human plasma‐derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone , 2003, Vox sanguinis.
[11] S. Fujita,et al. Clinical Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Recombinant Factor VIIa in Japanese Patients With Hemophilia With Inhibitors , 2001, International journal of hematology.
[12] S. Carlsson,et al. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. , 2001, Thrombosis research.
[13] W. T. Sawyer,et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa , 1994, Clinical pharmacology and therapeutics.
[14] Y Komiyama,et al. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. , 1990, Biochemistry.
[15] K. Mori,et al. Congenital factor X deficiency in Japan. , 1981, The Tohoku journal of experimental medicine.